CORRECTION article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1667245
This article is part of the Research TopicBiomarkers in Genitourinary Cancers, Volume IIView all 26 articles
Correction: MED10 Drives the Oncogenicity and Refractory Phenotype of Bladder Urothelial Carcinoma Through the Upregulation of hsa-miR-590
Provisionally accepted
- Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
In the published article, there was an error. The published article did not fully disclose the source of the human tissue samples or provide complete information about the relevant ethical approvals, including a noted non-compliance (NC) event.A correction has been made to 1. Materials and Methods -Bladder Cancer Tissue Samples (paragraph 1); and 2. ETHICS STATEMENT. Bladder Cancer Tissue Samples Bladder UC tissue samples (n = 79) were obtained from the Taipei Medical University -Shuang Ho Hospital tissue bank. The study was approved by the Institutional Review Board of the Taipei Medical University (approval number: N202102034) and was compliant with recommendations from the Declaration of Helsinki for biomedical research involving human subjects. The requirement for patients' signed informed consent was waived because of the retrospective nature of the study. Bladder Cancer Tissue Samples A total of 79 archived tissue specimens diagnosed with bladder urothelial carcinoma (UC) were retrieved from the Department of Pathology at Taipei Medical University-Shuang Ho Hospital. These samples were originally collected for routine clinical diagnostic purposes and subsequently preserved in the hospital's pathology archives. As the research was retrospective and involved the analysis of previously collected, fully de-identified specimens, the Institutional Review Board (IRB) of Taipei Medical University reviewed the protocol. It addressed a related non-compliance (NC) event. Upon review, the IRB concluded that the non-compliance of this study was appropriately managed and that corrective measures were implemented in accordance with ethical and regulatory standards governing human subject research. This section previously read: The studies involving human participants were reviewed and approved by the Joint Institutional Review Board (JIRB) of Taipei Medical University. The procurement of the samples was strictly adherent to the approved IRB (No. N202102034) issued by the JIRB. Informed consent was waived because of the retrospective nature of the study. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. ETHICS STATEMENT A total of 79 archived bladder urothelial carcinoma (UC) specimens were obtained from the Pathology Department of Taipei Medical University-Shuang Ho Hospital. These samples, originally collected for clinical diagnostics, were fully de-identified. The Institutional Review Board reviewed and addressed a related non-compliance (NC) event, confirming that appropriate corrective actions were taken in line with ethical and regulatory standards.The authors apologize for these errors and confirm that they do not affect the scientific conclusions of the article in any way. The original article has been updated accordingly.
Keywords: Bladder urothelial carcinoma, MED10, hsa-miR-590, metastasis, Cancer stemness, disease progression, Recurrence, therapy failure
Received: 16 Jul 2025; Accepted: 08 Aug 2025.
Copyright: © 2025 Wu, WANG, Hu, Wu, Yeh and Bamodu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Chi-Tai Yeh, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan
Oluwaseun Adebayo Bamodu, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.